Abiomics Europe Ltd.
Abiomics Europe Ltd. is a technology startup company that was founded in 2009 by bioinformatics and biomedical researchers along with investors. The cooperation between the Semmelweis University, Department of Genetics, Cell- and Immunobiology and the Budapest University of Technology and Economics, Department of Measurement and Information Systems started in 2005 and led to the establishment of the company.
Company details
Find locations served, office locations
- Business Type:
- Service provider
- Industry Type:
- Medical / Health Care
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
The grand promises of the postgenomic era are the academic, systems biologic understanding of the normal and disease states at physiological, cognitive, and emotional levels; the personalized prevention, diagnosis, drugs, and treatments of diseases significant in public health; and rational drug design in the pharma industry. However it is more and more clear that their fulfillment requires new technological breakthroughs to measure unprecedented genomic, proteomic, metabolomic, or immunomic profiles, new solutions for the representation of biomedical knowledge, new approaches to induction for statistical and causal inferences. A key factor for the integration of the myriads of biological knowledge items (mega-scale memes) and omic data (giga- and tera-scale data from multiple levels) is the efficient use of massive computational resources (tera- and peta-scale computing).
For the field of knowledge representation, knowledge engineering, and decision support, the central role of biomedicine is unchallenged from the birth of this field. However the explosion of the sheer amount of electronically available biomedical knowledge, its use in supporting the design of experiments and data collection, its transformation to a form eligible for the incorporation in inductive inference, and the fusion of the uncertain results of inductive inference with factual knowledge to support the interpretation of the data analysis pose serious new challenges.
Within the biomedical world it became evident that the understanding of the deciphered human genome requires the understanding of the effects of its evolutionary (phylogenetic), population level (germ-line), and individual (somatic) variations, besides other artificial perturbations and interventions. Today thousands of complete genomes are available. The exploration of the genetic and epigenetic germline variations has been accelerated in the last decade. Currently the complete genomic exploration of somatic mutations has started, such as in tumorgenetics and immunomics, and more and more complete and exact proteomic, lipidomic, and metabolomic profiles are available, which are more and more complex as dependent on the environment and life style. Another extension is the exploration of symbiotic organisms as well using metagenomics.
For inductive inference, the main challenges of the high-throughput era of biomedicine are the high-dimensional data sets, the small sample size, and the easy access and multiple use of many data sets, besides standard, though pressing issues such as the use of incomplete data. The most important responses are based on the incorporation of prior knowledge and the use of massive amount of computer power. Monte Carlo methods in Bayesian statistics and resampling techniques from the field of computer intensive statistics are good examples for the applied computer intensive techniques. The loss of the leading position of nuclear simulations at the field of high-performance computing was a surprise five years ago, but the pioneering role of bioinformatics is well recognised today.
Thus biomedical research is at the crossroad of knowledge engineering, decision support, inductive inference (statistics), and high-performance computation.
By realizing this constellation, the focus of Abiomics Europe provides tools for the complete chain of study design, data analysis, interpretation, and decision support, with particular emphases on the integration of data from heterogeneous levels and the fusion of background knowledge. Specifically we offer tools for the following:
- Sequential study design
- Biomarker analysis
- Knowledge base technologies for metaanalysis
- Clinical decision support
- Target and lead prioritization by repositioning
- Save a drug by personalization
History
The 5 years of cooperation and joint projects made it clear that modern life science research and development is not possible anymore without advanced information technology support. The GenaGrid consortium was founded in 2008 with the support of the National Office for Research and Technology when new academic and industry partners joined the research group and aims to develop various bioinformatics services. Abiomics Europe Ltd. is the company responsible for the utilization for the intellectual properties of the consortium and has all the exclusive rights for the developed technologies. Abiomics Europe drives the business development, market research and marketing activities for the consortium.
The GenaGrid research group and Abiomics Europe employs almost 30 informaticians and biomedical researchers. The group engages the technologies and software in Asthma and ALL research. The GenaGrid research group operates a genomics lab and the most powerful grid supercomputer dedicated for life science research in Hungary with 512 CPUs (March 2010).
Mission
Abiomics Europe was founded to make the intellectual properties and technologies developed by the GenaGrid research group accessible to all of our academic or industry partners who face the challenges of managing and analyzing complex life science data. Our specialists at Abiomics Europe have all the skills and infrastructure to support clinical, biomedical, pharma and biotech research and development projects where information technology challenges arise. The profile of the company consists among others:
- Systems Biology consultation services
- Adaptive study design
- Bioinformatics and biostatistics analysis
- Biomarker discovery technologies
- IT support for drug repositioning
- Text Mining technologies
- Clinical and pharma decision support technologies
- Biobanking and very large scale probabilistic knowledge bases
With the leading technologies of the research group we aim to reach the international market, but we are intended on cooperating with all the Hungarian life science and pharma research groups who don’t have a professional in-house bioinformatics or biostatistics group.
